date,title,source
Oct-31-18,Scholar Rock to Present at the Jefferies 2018 London Healthcare Conference,GlobeNewswire
Nov-09-18,Scholar Rock Demonstrates that Highly Specific TGF1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy,GlobeNewswire
Nov-19-18,Scholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors,GlobeNewswire
Nov-27-18,Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy,GlobeNewswire
Nov-29-18,Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference,GlobeNewswire
Dec-03-18,Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy,GlobeNewswire
Dec-19-18,Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases,Business Wire
Dec-20-18,Raymond James: Gilead In NASH For The Long Haul,Benzinga
Dec-26-18,"Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal",Zacks
Dec-28-18,"Why Cabot Oil & Gas, Uxin, and Scholar Rock Holding Slumped Today",Motley Fool
Jan-03-19,Gilead Stock Breaks Out to Channel Resistance,Investopedia
Jan-03-19,Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference,GlobeNewswire
Jan-04-19,Read This Before Selling Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares,Simply Wall St.
Feb-15-19,Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review,Zacks
Feb-26-19,Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans,GlobeNewswire
Mar-06-19,Scholar Rock to Participate in Upcoming Investor Conferences,GlobeNewswire
Mar-12-19,"Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGF1 Activation, to Overcome Checkpoint Inhibitor Resistance",GlobeNewswire
Mar-18-19,Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress,GlobeNewswire
Apr-02-19,Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGF1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression with Combination Therapy,GlobeNewswire
Apr-11-19,"Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources",GlobeNewswire
Apr-30-19,"Scholar Rock Appoints Akshay Vaishnaw, M.D., Ph.D. to Its Board of Directors",GlobeNewswire
May-08-19,Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy,GlobeNewswire
May-09-19,Is Scholar Rock Holding Corporation (SRRK) A Good Stock To Buy?,Insider Monkey
May-14-19,Scholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress,GlobeNewswire
May-28-19,Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference,GlobeNewswire
Jun-03-19,Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers,GlobeNewswire
Jun-18-19,Scholar Rock Announces Proposed Public Offering of Common Stock,GlobeNewswire
Jun-19-19,Scholar Rock Announces Pricing of Public Offering of Common Stock,GlobeNewswire
Jun-19-19,Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference,GlobeNewswire
